Contineum Therapeutics, Inc. - Common stock (CTNM) earnings
CTNM earnings moved a median of +2.85% by the close. Quarterly and annual CTNM reports and results, each read against the price at its own news timestamp. Back to the CTNM overview →
22 measured CTNM earnings events.
Where these CTNM earnings landedvs 22 measured CTNM earnings reactions
| Middle 50% of CTNM earnings reactions | -1.65% to +5.08% |
|---|---|
| Median reaction (to close) | +2.85% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 CTNM earnings events with a measured close landed between -1.65% and +5.08%; 68% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Contineum Therapeutics Reports Third-Quarter 2026 Financial Results | Press release | +0.53% | -2.10% | |
| Form 10-Q Contineum Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.53% | -2.10% | |
| Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones | Press release | +0.79% | -1.65% | |
| Form 10-Q Contineum Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.79% | -1.65% | |
| Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones | Press release | -0.55% | +3.11% | |
| Form 10-Q Contineum Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.55% | +3.11% | |
| Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones | Press release | -4.62% | -5.64% | |
| Form 10-K Contineum Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -4.62% | -5.64% | |
| Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones | Press release | +0.38% | +3.58% | |
| Form 10-Q Contineum Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.38% | +3.58% | |
| Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones | Press release | -2.91% | +2.43% | |
| Form 10-Q Contineum Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -2.91% | +2.43% | |
| Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones | Press release | +0.00% | +2.60% | |
| Form 10-Q Contineum Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +2.60% | |
| Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones | Press release | +0.00% | +5.78% | |
| Form 10-K Contineum Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +5.78% | |
| Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Press release | +0.92% | +6.98% | |
| Form 10-Q Contineum Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.92% | +6.98% | |
| Form 10-Q Contineum Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | — | -2.76% | |
| Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | Press release | +0.00% | +5.56% | |
| Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | Press release | +0.00% | +5.08% | |
| Form 10-Q Contineum Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +5.08% |
Keep exploring
More CTNM: analyst actions → · SEC filings → · CTNM overview →